Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Martin DL et al. | Serology for trachoma surveillance after cessation of mass drug administration. | 2015 | PLoS Negl Trop Dis | pmid:25714363 |
| Abdulai AA et al. | Community-based mass treatment with azithromycin for the elimination of yaws in Ghana-Results of a pilot study. | 2018 | PLoS Negl Trop Dis | pmid:29566044 |
| Mulugeta A et al. | Coverage, social mobilization and challenges of mass Zithromax administration campaign in South and South East zones of Tigray, Northern Ethiopia: A cross sectional study. | 2018 | PLoS Negl Trop Dis | pmid:29481558 |
| Ghinai R et al. | A cross-sectional study of 'yaws' in districts of Ghana which have previously undertaken azithromycin mass drug administration for trachoma control. | 2015 | PLoS Negl Trop Dis | pmid:25632942 |
| Astale T et al. | Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia. | 2018 | PLoS Negl Trop Dis | pmid:29451881 |
| Goodhew EB et al. | CT694 and pgp3 as serological tools for monitoring trachoma programs. | 2012 | PLoS Negl Trop Dis | pmid:23133684 |
| Ayele B et al. | Risk factors for ocular chlamydia after three mass azithromycin distributions. | 2011 | PLoS Negl Trop Dis | pmid:22180804 |
| Sanders AM et al. | Burden of trachoma in five counties of Eastern Equatoria state, South Sudan: Results from population-based surveys. | 2017 | PLoS Negl Trop Dis | pmid:28614375 |
| Houinei W et al. | Haemophilus ducreyi DNA is detectable on the skin of asymptomatic children, flies and fomites in villages of Papua New Guinea. | 2017 | PLoS Negl Trop Dis | pmid:28489855 |
| Lakew T et al. | Reduction and return of infectious trachoma in severely affected communities in Ethiopia. | 2009 | PLoS Negl Trop Dis | pmid:19190781 |
| Amza A et al. | Does mass azithromycin distribution impact child growth and nutrition in Niger? A cluster-randomized trial. | 2014 | PLoS Negl Trop Dis | pmid:25210836 |
| Harding-Esch EM et al. | Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. | 2013 | PLoS Negl Trop Dis | pmid:23785525 |
| Haque F et al. | Evaluation of a Smartphone Decision-Support Tool for Diarrheal Disease Management in a Resource-Limited Setting. | 2017 | PLoS Negl Trop Dis | pmid:28103233 |
| Edwards T et al. | Non-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factors. | 2014 | PLoS Negl Trop Dis | pmid:25165994 |
| Kwakye-Maclean C et al. | A Single Dose Oral Azithromycin versus Intramuscular Benzathine Penicillin for the Treatment of Yaws-A Randomized Non Inferiority Trial in Ghana. | 2017 | PLoS Negl Trop Dis | pmid:28072863 |
| Ssemanda EN et al. | Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds. | 2012 | PLoS Negl Trop Dis | pmid:22448296 |
| West SK et al. | A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. | 2013 | PLoS Negl Trop Dis | pmid:24009792 |
| Marks M et al. | Prevalence of Active and Latent Yaws in the Solomon Islands 18 Months after Azithromycin Mass Drug Administration for Trachoma. | 2016 | PLoS Negl Trop Dis | pmid:27551787 |
| Burr SE et al. | Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. | 2013 | PLoS Negl Trop Dis | pmid:23936573 |
| Emerson PM and Ngondi J | Mass antibiotic treatment alone does not eliminate ocular chlamydial infection. | 2009 | PLoS Negl Trop Dis | pmid:19333370 |
| Liu B et al. | Relationship between Community Drug Administration Strategy and Changes in Trachoma Prevalence, 2007 to 2013. | 2016 | PLoS Negl Trop Dis | pmid:27385309 |
| Ssemanda EN et al. | Mass treatment with azithromycin for trachoma control: participation clusters in households. | 2010 | PLoS Negl Trop Dis | pmid:20957196 |
| Blake IM et al. | Targeting antibiotics to households for trachoma control. | 2010 | PLoS Negl Trop Dis | pmid:21072225 |
| El-Tahtawy A et al. | The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis. | 2008 | PLoS Negl Trop Dis | pmid:18478051 |
| Amza A et al. | Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops. | 2010 | PLoS Negl Trop Dis | pmid:21124889 |
| Ngondi J et al. | Associations between active trachoma and community intervention with Antibiotics, Facial cleanliness, and Environmental improvement (A,F,E). | 2008 | PLoS Negl Trop Dis | pmid:18446204 |
| Lietman TM et al. | Identifying a sufficient core group for trachoma transmission. | 2018 | PLoS Negl Trop Dis | pmid:30296259 |
| Solomon AW et al. | Trachoma and Yaws: Common Ground? | 2015 | PLoS Negl Trop Dis | pmid:26633176 |
| King JD et al. | Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution. | 2014 | PLoS Negl Trop Dis | pmid:24625539 |
| Cajas-Monson LC et al. | Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania. | 2011 | PLoS Negl Trop Dis | pmid:21423645 |
| Marks M et al. | Impact of Community Mass Treatment with Azithromycin for Trachoma Elimination on the Prevalence of Yaws. | 2015 | PLoS Negl Trop Dis | pmid:26241484 |
| Andreasen AA et al. | Chlamydia trachomatis ompA variants in trachoma: what do they tell us? | 2008 | PLoS Negl Trop Dis | pmid:18820750 |
| Amza A et al. | Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial. | 2012 | PLoS Negl Trop Dis | pmid:22545165 |
| Vlieghe ER et al. | Azithromycin and ciprofloxacin resistance in Salmonella bloodstream infections in Cambodian adults. | 2012 | PLoS Negl Trop Dis | pmid:23272255 |
| Kalua K et al. | One round of azithromycin MDA adequate to interrupt transmission in districts with prevalence of trachomatous inflammation-follicular of 5.0-9.9%: Evidence from Malawi. | 2018 | PLoS Negl Trop Dis | pmid:29897902 |
| Harding-Esch E et al. | Costs of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET study. | 2015 | PLoS Negl Trop Dis | pmid:25901349 |
| Kolaczinski JH et al. | The cost of antibiotic mass drug administration for trachoma control in a remote area of South Sudan. | 2011 | PLoS Negl Trop Dis | pmid:22022632 |
| Lee JS et al. | The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children. | 2014 | PLoS Negl Trop Dis | pmid:24722392 |
| Zmora N et al. | Open label comparative trial of mono versus dual antibiotic therapy for Typhoid Fever in adults. | 2018 | PLoS Negl Trop Dis | pmid:29684022 |
| Jimenez V et al. | Mass drug administration for trachoma: how long is not long enough? | 2015 | PLoS Negl Trop Dis | pmid:25799168 |
| van den Broek NR et al. | The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. | 2009 | PLoS Med. | pmid:19956761 |
| Wright HR et al. | Trachoma and the need for a coordinated community-wide response: a case-based study. | 2006 | PLoS Med. | pmid:16492074 |
| Amland PF et al. | A prospective, double-blind, placebo-controlled trial of a single dose of azithromycin on postoperative wound infections in plastic surgery. | 1995 | Plast. Reconstr. Surg. | pmid:7480237 |
| Costa IN et al. | Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). | 2009 | Placenta | pmid:19703714 |
| Franco PS et al. | Azithromycin and spiramycin induce anti-inflammatory response in human trophoblastic (BeWo) cells infected by Toxoplasma gondii but are able to control infection. | 2011 | Placenta | pmid:21908042 |
| Cheng B | Advances in prevention and treatment of MAC. | 1995 | PI Perspect | pmid:11363104 |
| An J et al. | Antibacterial and synergy of a flavanonol rhamnoside with antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). | 2011 | Phytomedicine | pmid:21466953 |
| Stieger N et al. | Solution-mediated crystallization of amorphous azithromycin. | 2017 | Pharmazie | pmid:29441902 |
| Feng X and Liu J | A combination of irsogladine maleate and azithromycin exhibits addictive protective effects in LPS-induced human gingival epithelial cells. | 2017 | Pharmazie | pmid:29441859 |
| Okayasu S et al. | A survey on diarrhea and convenience of intake associated with a single-dose extended release formulation of azithromycin. | 2011 | Pharmazie | pmid:21553656 |
| Xue-Min Z et al. | Determination of azithromycin in human plasma by LC-MS-MS and its pharmacokinetics. | 2007 | Pharmazie | pmid:17484278 |
| Togami K et al. | Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. | 2012 | Pharmazie | pmid:22764569 |
| Zhu C et al. | Azithromycin inhibits double-stranded RNA-induced thymic stromal lymphopoietin release from human airway epithelial cells. | 2013 | Pharmazie | pmid:24380240 |
| Hamdan II | Comparative in vitro investigations of the interaction between some macrolides and Cu(II), Zn(II) and Fe(II). | 2003 | Pharmazie | pmid:12685822 |
| Odendaal RW et al. | A novel reversed-phase LC method for quantitative detection of azithromycin in bulk drug and tablet formulations in various aqueous media. | 2012 | Pharmazie | pmid:23346759 |
| Najib MM et al. | Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. | 2000 | Pharmacotherapy | pmid:10772376 |
| Pollak PT and Slayter KL | Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction. | 1997 Jul-Aug | Pharmacotherapy | pmid:9250566 |
| Bizjak ED et al. | Intravenous azithromycin-induced ototoxicity. | 1999 | Pharmacotherapy | pmid:10030778 |
| Toltzis P | Comparison of amoxicillin with alternative agents for the treatment of acute otitis media in children. | 2005 | Pharmacotherapy | pmid:16305281 |
| Shrader SP et al. | Azithromycin and warfarin interaction. | 2004 | Pharmacotherapy | pmid:15303459 |
| Gaylor AS and Reilly JC | Therapy with macrolides in patients with cystic fibrosis. | 2002 | Pharmacotherapy | pmid:11837560 |
| Beckey NP et al. | Retrospective evaluation of a potential interaction between azithromycine and warfarin in patients stabilized on warfarin. | 2000 | Pharmacotherapy | pmid:10999497 |
| Drew RH and Gallis HA | Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications. | 1992 | Pharmacotherapy | pmid:1319048 |
| Page RL et al. | Possible interaction between intravenous azithromycin and oral cyclosporine. | 2001 | Pharmacotherapy | pmid:11714218 |
| Ernst EJ et al. | Comparison of the serum and intracellular pharmacokinetics of azithromycin in healthy and diabetic volunteers. | 2000 | Pharmacotherapy | pmid:10853621 |
| Prescott WA and Johnson CE | Antiinflammatory therapies for cystic fibrosis: past, present, and future. | 2005 | Pharmacotherapy | pmid:15977917 |
| Eschenauer G et al. | Azithromycin-warfarin interaction: are we fishing with a red herring? | 2005 | Pharmacotherapy | pmid:15977924 |
| Woodruff AE et al. | Azithromycin-Induced, Biopsy-Proven Acute Interstitial Nephritis in an Adult Successfully Treated with Low-Dose Corticosteroids. | 2015 | Pharmacotherapy | pmid:26598102 |
| Stevens RC et al. | Pharmacokinetics of azithromycin after single- and multiple-doses in children. | 1997 Sep-Oct | Pharmacotherapy | pmid:9324176 |
| Destache CJ et al. | Microbiologic effect of bovine cerebrospinal fluid and azithromycin against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. | 1997 Sep-Oct | Pharmacotherapy | pmid:9324186 |
| LaPlante KL et al. | Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. | 2008 | Pharmacotherapy | pmid:18154478 |
| Tilelli JA et al. | Life-threatening bradyarrhythmia after massive azithromycin overdose. | 2006 | Pharmacotherapy | pmid:16506357 |
| Petitta A et al. | Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department. | 1999 | Pharmacotherapy | pmid:10331829 |
| Foster DR and Milan NL | Potential interaction between azithromycin and warfarin. | 1999 | Pharmacotherapy | pmid:10417043 |
| McCall KL et al. | Determination of the lack of a drug interaction between azithromycin and warfarin. | 2004 | Pharmacotherapy | pmid:14998219 |
| Poachanukoon O et al. | Macrolides attenuate phorbol ester-induced tumor necrosis factor-α and mucin production from human airway epithelial cells. | 2014 | Pharmacology | pmid:24556631 |
| Parnham MJ et al. | Azithromycin: mechanisms of action and their relevance for clinical applications. | 2014 | Pharmacol. Ther. | pmid:24631273 |
| Di Paolo A et al. | Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. | 2002 | Pharmacol. Res. | pmid:12457629 |
| Baschiera F et al. | Improved tonsillar disposition of azithromycin following a 3-day oral treatment with 20 mg kg(-1) in paediatric patients. | 2002 | Pharmacol. Res. | pmid:12208127 |
| Matijašić M et al. | Fluorescently labeled macrolides as a tool for monitoring cellular and tissue distribution of azithromycin. | 2012 | Pharmacol. Res. | pmid:22749903 |
| Banjanac M et al. | Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells. | 2012 | Pharmacol. Res. | pmid:22766077 |
| Graziani F et al. | Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction. | 2005 | Pharmacol. Res. | pmid:16140544 |
| Bachmann K et al. | Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. | 2003 | Pharmacol. Res. | pmid:12742010 |
| Marjanović N et al. | Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. | 2011 | Pharmacol. Res. | pmid:21315154 |
| Szałek E et al. | Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not? | 2012 | Pharmacol Rep | pmid:23406766 |
| He XJ et al. | Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. | 2009 Sep-Oct | Pharmacol Rep | pmid:19904007 |
| Fohner AE et al. | PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. | 2017 | Pharmacogenet. Genomics | pmid:28146011 |
| Quach C et al. | Effectiveness of amoxicillin, azithromycin, cefprozil and clarithromycin in the treatment of acute otitis media in children: a population-based study. | 2005 | Pharmacoepidemiol Drug Saf | pmid:15386697 |
| Palcevski G et al. | Antibiotic use profile at paediatric clinics in two transitional countries. | 2004 | Pharmacoepidemiol Drug Saf | pmid:15072118 |
| Goldstein LH et al. | Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia. | 2015 | Pharmacoepidemiol Drug Saf | pmid:26238864 |
| Bérard A et al. | Use of macrolides during pregnancy and the risk of birth defects: a population-based study. | 2015 | Pharmacoepidemiol Drug Saf | pmid:26513406 |
| Lea AP and Lamb HM | Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women. | 1997 | Pharmacoeconomics | pmid:10174326 |
| Zhong M et al. | Azithromycin cationic non-lecithoid nano/microparticles improve bioavailability and targeting efficiency. | 2014 | Pharm. Res. | pmid:25208873 |
| Wang Z and Meenach SA | Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections. | 2016 | Pharm. Res. | pmid:27091030 |
| Curatolo W | Interdisciplinary science and the design of a single-dose antibiotic therapy. | 2011 | Pharm. Res. | pmid:21311957 |
| Curatolo W et al. | Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules. | 2011 | Pharm. Res. | pmid:21331473 |
| Berquand A et al. | Interaction of the macrolide antibiotic azithromycin with lipid bilayers: effect on membrane organization, fluidity, and permeability. | 2005 | Pharm. Res. | pmid:15835753 |
| Chanteux H et al. | Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. | 2003 | Pharm. Res. | pmid:12739771 |
| Evans LA et al. | Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. | 1996 | Pharm. Res. | pmid:8899856 |
| Curatolo W et al. | Mechanistic study of the azithromycin dosage-form-dependent food effect. | 2010 | Pharm. Res. | pmid:20372991 |